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Abstract 24 
Reconstitution of T cell immunity is absolutely critical for the effective control of virus-25 
associated infectious complications in hematopoietic stem cell transplant (HSCT) recipients.  26 
Co-infection with genetic variants of human cytomegalovirus (CMV) in transplant recipients 27 
has been linked to clinical disease manifestation, however how these genetic variants 28 
impact on T cell immune reconstitution remains poorly understood. Here we have evaluated 29 
dynamic changes in the emergence of genetic variants of CMV in HSCT recipients and 30 
correlated these changes with reconstitution of anti-viral T cell responses. Analysis of single 31 
nucleotide polymorphisms within sequences encoding HLA class I-restricted CMV epitopes 32 
from the immediate early 1 gene of CMV revealed that co-infection with genetically distinct 33 
variants of CMV was detected in 52% of patients.  However in spite of exposure to multiple 34 
viral variants, the T cell responses in these patients were preferentially directed to a limited 35 
repertoire of HLA class I-restricted CMV epitopes, either conserved, variant or cross-36 
reactive. More importantly, we also demonstrate that long-term control of CMV infection 37 
after HSCT is primarily mediated through the efficient induction of a stable anti-viral T cell 38 
immunity irrespective of the nature of the antigenic target. These observations provide 39 
important insights for the future design of anti-viral T cell-based immunotherapeutic 40 
strategies for transplant recipients emphasising the critical impact of robust immune 41 
reconstitution for efficient control of viral infection.  42 
 43 
 44 
  45 
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Importance 46 
Infection and disease caused by human Cytomegalovirus (CMV) remains a significant 47 
burden in patients undergoing haematopoietic stem cell transplantation (HSCT).The 48 
establishment of efficient immunological control, primarily mediated by cytotoxic T cells 49 
plays a critical role in preventing CMV-associated disease in transplant recipients. Recent 50 
evidence has also begun to investigate the impact genetic variation in CMV has upon 51 
disease outcome in transplant recipients. In this study we sought to investigate the role T 52 
cell immunity plays in recognising and controlling genetic variants of CMV. We demonstrate 53 
that while a significant proportion of HSCT recipients may be exposed to multiple genetic 54 
variants of CMV, this does not necessarily lead to immune control mediated via recognition 55 
of this genetic variation. Rather immune control is associated with the efficient 56 
establishment of a stable immune response predominantly directed against 57 
immunodominant conserved T cell epitopes.  58 
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Introduction 59 
 Allogeneic hematopoietic stem cell transplantation (HSCT) can be curative of life 60 
threatening hematological malignancies. However, due to the underlying immunodeficiency 61 
associated with HSCT and as a consequence of the immunosuppressive regimes used to 62 
prevent graft versus host disease following HSCT, infectious complications remain a 63 
significant burden to the treatment modality. One significant infectious complication 64 
following HSCT is caused by the ubiquitous pathogen, human Cytomegalovirus (CMV) (1).  A 65 
member of the human β-Herpesvirus family, CMV is highly prevalent across populations and 66 
is typically a lifelong asymptomatic infection in immunocompetent individuals. However, 67 
CMV is a leading cause of viral complications in immunocompromised individuals (2). This is 68 
particularly evident in the absence of CMV-specific immunological memory, including in 69 
CMV-seropositive HSCT recipients (R+) who receive a transplant from a seronegative donor 70 
(D-), and are at a higher risk of CMV reactivations and associated complications, including 71 
enterocolitis and pneumonitis (3-5). Current therapeutic strategies to control CMV 72 
reactivation in HSCT recipients predominantly involve the pre-emptive administration of 73 
ganciclovir to control CMV following detection of viral reactivation (6). Through the use of 74 
immunological monitoring approaches, it is becoming apparent that the prevention of viral 75 
reactivation and the long-term control of CMV infection are dependent upon the induction 76 
of robust and stable CMV-specific immunological memory (7-10).  77 
 78 
Recent studies have suggested that in addition to the efficiency of immunological 79 
control of CMV, exposure to genotypically distinct variants of CMV may also have an impact 80 
on clinical outcome following transplant. Genotypic analysis of surface CMV glycoproteins 81 
have shown that immunocompromised patients, both HSCT and solid organ transplant (SOT) 82 
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recipients, are commonly co-infected with multiple genotypically distinct CMV variants (11, 83 
12). It has also been demonstrated that SOT recipients show an increased duration of 84 
viraemia following reactivation of multiple genotypic isolates (12), suggesting potentially 85 
reduced immunological control following co-infection. Despite these observations, and 86 
considering the critical role T cell immunity plays in the control of CMV, very little research 87 
has been performed that specifically examines the impact of genetically distinct variants of 88 
CMV on CMV-specific T cell immunity (13-15). While this is particularly relevant for R+/D- 89 
HSCT patients who are at increased risk of CMV-associated complications, immune control 90 
of CMV infection in R+/D+ recipients could also be impacted by exposure to distinct genetic 91 
viral variants of the recipient that are not efficiently controlled by pre-existing donor 92 
immunity  To address the impact genetic variation has upon T cell immunity we focused 93 
upon the immunodominant immediate early 1 (IE-1) of CMV that has previously been shown 94 
to encode significant genetic variation, including within immunodominant CD8+ T cell 95 
epitopes (13-15).  Using pyrosequencing analysis to identify genetic variation within IE-1, 96 
and IE-1 encoded epitope-specific T cell analysis, we sought to determine the impact of 97 
genetic variation and exposure to multiple viral variants on the induction of CMV-specific T 98 
cell immunity in a cohort of HSCT recipients.  99 
 100 
  101 
 o
n
 July 17, 2017 by CARDIFF UNIVERSITY
http://jvi.asm.org/
D
ow
nloaded from
 
6 
 
Materials and Methods 102 
Study Subjects 103 
 The study subjects were from a cohort of 46 allogeneic HSCT recipients who were 104 
recruited on an immune monitoring study approved by the Royal Brisbane and Women's 105 
Hospital Human Research Ethics Committes (Reference number 2006/192) (9, 16). All 106 
patients provided informed written consent. As described previously (9), all patients were 107 
monitored for CMV viral load using the COBAS Amplicator CMV Monitor Test (Roche 108 
Diagnostics, Basel, Switzerland) and CMV-specific T cell immunity using QuantiFERON-CMV 109 
assay (Cellestis, Carnegie, VIC, Australia). CMV reactivation was defined as the detection of 110 
>600 copies/ml CMV DNA.  111 
 112 
Detection of IE-1 variants using pyrosequencing  113 
DNA was extracted from plasma samples using the QIAamp DNA blood mini kit (Qiagen, 114 
USA). DNA PCR amplifications were performed using the PyroMark PCR kit (Qiagen, USA) in 115 
a standard 25µl reaction for 45 cycles. PCR amplification primers and the target sequences 116 
are as follows: IE1Start, forward primer GGAGATGTGGATGGCTTGTATT, reverse primer 117 
GCAGCCATTGGTGGTCTTA and sequencing primer  YATTCCTGTAGCACATATA (target 118 
sequence: MATCATCTTTCTCYTAAGTTCRTCCTT); IE1Middle forward primer 119 
TAAGACCACCAATGGCTGC, reverse primer CATACAAGCGTCACTRGTGACCT and sequencing 120 
primer AATCTTAAAKATYTTCTG (target sequence: GGMATAAGYCATAATCTCATCAGGG); 121 
IE1end, forward primer TYTGTCGRGTGCTGTGCTGYT, reverse primer 122 
CACCAGCGGTGGCCAAAGTGTAG and sequencing primers GRGTGCTGTGCTGYTA and 123 
AGGAGTCAGATGAGGAAR (target sequences: TRTCTTAGAGGAGACTAGTGTGWTGCTGG and 124 
AKGCTATTGYAGCCTACACTTTGGCC).  The IUPAC nucleotide code is shown for ambiguous 125 
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sites. PCR cycling conditions consisted of an initial 15min denaturation at 95°C and 45 cycles 126 
of 95°C for 30sec, 60°C for 30sec, and 40sec at 72°C. Pyrosequencing reactions were 127 
performed according to the manufacturer instructions using a Qiagen PyroMark Q24 128 
system. Amplification products were washed in a series of buffers, and single-stranded, 129 
biotinylated DNA products were hybridised to sequencing primers in a 24-well plate used at 130 
a final concentration of 0.375μM in 20 μl of annealing buffer. PCR amplification bias in 131 
patient samples was corrected through pyrosequencing analysis of DNA from three well 132 
characterised strains of HCMV; AD169, Toledo and TB40E. The limit of detection in this 133 
system is 5%, therefore only values greater than this threshold were considered significant.  134 
 135 
Establishment and maintenance of cell lines  136 
Polyclonal T cell lines specific for the IE-1 encoded variant epitopes listed in Table 2 137 
and for CMV-encoded conserved T cells epitopes (HLA-A1 restricted VTEHDTLLY and 138 
YSEHPTFTSQY, HLA-A2 restricted NLVPMVATV and FMDILTTCV, HLA-B7 Restricted 139 
RPHERNGFTVL and TPRVTGGGAM, and HLA-B8 restricted QIKVRVDMV) were generated 140 
following stimulation of PBMC with 1µg/ml of cognate peptide. Polyclonal T cell cultures 141 
were maintained in growth medium containing recombinant interleukin-2 (IL-2) and 142 
assessed for T cell specificity after two weeks.  143 
 144 
Intracellular Cytokine Staining 145 
Expanded polyclonal T cell lines were stimulated with 1µg/mL of peptide and 146 
incubated for four hours in the presence of Brefeldin A (BD Biosciences, USA). For functional 147 
avidity assays, T cells were stimulated in duplicate with 10-fold serial dilutions of peptide 148 
(ranging from 1µg/mL to 0.1ng/mL). Cells were then incubated with PerCP-Cy5.5 anti-CD8 149 
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(eBioscience, USA) and FITC anti-CD4 (BD Biosciences, USA), fixed and permeabilised using a 150 
BD Cytofix/Cytoperm kit and incubated with PE anti-IFN-γ (BD Biosciences, USA). Cell 151 
acquisition was performed using a BD LSRFortessa (BD Biosciences, USA). Post-acquisition 152 
analysis was performed using FlowJo software (TreeStar, USA).  153 
 154 
Statistical Analysis 155 
 All statistical analysis was performed using Prism 6 Software (GraphPad Software, 156 
USA). Statistical differences were assessed using the non-parametric Mann Whitney Test. 157 
Data were considered statistical significant when p<0.05. 158 
  159 
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Results 160 
Dynamics of the emergence of genetic variants of CMV following viral reactivation in HSCT 161 
recipients 162 
Twenty six patients undergoing allogeneic HSCT were enrolled on this study 163 
following informed consent (9, 16).  The clinical characteristics of these patients are listed 164 
on Table 1. All patients received a T cell-replete bone marrow or G-CSF-mobilised peripheral 165 
blood stem cell graft and none had in vivo T cell depletion. CMV-seropositive patients or 166 
patients who received a transplant from a seropositive donor were treated prophylactically 167 
with high dose acyclovir from day -5 to day 28 or until discharge, then with valganciclovir 168 
until day 100. Patients with CMV DNAemia in plasma of >600 copies/mL were treated with 169 
ganciclovir 5mg/kg twice daily for 14 days, followed by once daily maintenance until plasma 170 
DNAemia was <600 copies/mL; or valganciclovir at 900mg twice daily followed by 900mg 171 
once daily for maintenance. Foscarnet was used in patients who were nonresponsive or 172 
displayed significant toxicity from ganciclovir. Of the 26 HSCT recipients enrolled for this 173 
study, 17 had viral reactivation as defined by CMV DNAemia >600 copies/ml. All of these 174 
patients were CMV-seropositive prior to transplant: twelve had a CMV-seronegative donor 175 
(characterised as R+/D- recipients), while the remaining five had a CMV-seropositive donor 176 
(characterised as R+/D+ recipients). Early CMV reactivation developed in 16 of these 177 
patients, while 4 patients had late CMV reactivation which occurred beyond the first 100 178 
days post-transplant was detected in 4. Two of the late CMV reactivation patients 179 
developed CMV-associated disease: one colitis and one enteritis. Fourteen of the seventeen 180 
displayed an unstable CMV-specific immune response, as assessed by CMV-QuantiFERON 181 
assay, and characterised by a failure to generate a stable CMV-specific IFN-γ response by 59 182 
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days post-transplant (9). All nine patients included in the current study who demonstrated 183 
CMV-immune reconstitution also were without evidence of viral reactivation.     184 
 185 
To delineate the impact of the emergence of genetic variants on T cell immune 186 
reconstitution in this cohort of HSCT recipients, we focused on eight HLA class I-restricted 187 
CD8+ T cell epitopes from the Immediate Early (IE-1) protein of CMV (Table 2). Three novel 188 
epitopes were mapped during this study (Table 2) and five epitopes have been previously 189 
described (17-21). Using the Genbank database we were able to identify a series of variant 190 
sequences for each of these epitopes. We designed a pyrosequencing analysis to identify 191 
the single nucleotide polymorphisms (SNPs) within the CMV-encoded CD8+ T cell 192 
epitopes.Initially, these SNP analyses were carried out at the peak of viral load in all HSCT 193 
recipients who showed CMV reactivation. The amino acid residue at each variant position 194 
was extrapolated based upon the nucleotide sequence. Data in Fig 1 represents the 195 
proportion of recipients showing either one or both amino acids at each position. Data was 196 
corrected for error rates at each position as outlined in the Materials and Methods. 197 
Although we observed bias in amino acid usage at certain positions, we noted the 198 
preferential usage of particular amino acid residues was similar in the R+/D- (Fig 1A) and the 199 
R+/D+ (Fig 1B) cohorts . This analysis also revealed a high proportion of HSCT recipients had 200 
multiple IE-1 variants following reactivation, whereby 6-40% of the samples demonstrated 201 
both variant amino acids and 9-of-17 HSCT recipients (5-of-12 R+/D- and 2 of 5 R+/D+) 202 
showed definitive evidence of mixed infection characterised by the concurrent detection of 203 
both variant residues on at least one position.  204 
 205 
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We subsequently assessed the stability of the viral variants over time, using 206 
longitudinal plasma samples during viral reactivation from 16 of the 17 HSCT recipients. 207 
Representative longitudinal analysis of all SNPs assessed in individual patients is shown in 208 
Figure 2. Whilst some HSCT recipients, including both R+/D- and R+/D+ patients showed 209 
very little change in the pattern of SNP expression either following detection of 210 
predominantly single variant (recipient 4) or multiple variants (recipient 17), other HSCT 211 
recipients demonstrate changes in SNP frequency during periods of viral reactivation. This is 212 
particularly evident in the D+/R+ patient 19.  213 
Impact of co-infection on the T cell kinetics  214 
We next sought to assess the impact of epitope variation and co-infection on IE-1 215 
specific T cell immunity. As the frequency of IE1-specific T cells was too low in the majority 216 
of patients for direct ex vivo analysis, PBMC from HSCT recipients showing evidence of viral 217 
reactivation were stimulated with all potentially HLA-matched variant peptide epitopes 218 
(Table 2) then cultured in vitro for two weeks in the presence of IL-2. PBMC from nine HSCT 219 
recipients showing immune reconstitution with no evidence of CMV reactivation were also 220 
stimulated with HLA-matched variant peptide epitopes (Table 2). As a control, PBMC were 221 
stimulated with at least two conserved HLA matched epitopes. Representative longitudinal 222 
analysis from three of these patients overlaid with viral reactivation kinetics is shown in Figs 223 
3A-C. An overall summary of the number of HSCT recipients tested for each epitope and the 224 
number of responding HSCT recipients is shown in Table 3. Interestingly, these observations 225 
suggested that while some patients could efficiently recognise multiple viral variants 226 
detected by pyrosequencing analysis (represented by patient 28, Figs 3B and 3E) others 227 
showed preferential recognition, in some instances targeted against subdominant epitope 228 
variants. As evidenced in Fig 3D, pyrosequencing analysis revealed that the IE-1 sequence in 229 
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recipient 17 at amino acid residues 201 and 205 was dominated by the amino acid residues 230 
R and M, which would correspond to the ELRRKMMYM epitope in HLA-B8 individuals. 231 
Despite this, recipient 17 only generated a T cell response against the subdominant 232 
ELKRKMIYM variant (Fig 3A). Interestingly, recipient 17 also showed the absence of a 233 
detectable response against the immunodominant conserved T cell epitope, VTEHDTTLY 234 
during viral reactivation and failed to generate a T cell response against the dominant 235 
ELRRKMMYM variant even after resolution of viral infection. Similar observations were 236 
evident for recipient 44 (Fig 3F), whereby we could detect sequences encoding both of the 237 
HLA-B44 variants, but were unable to detect a response against the DELKRKMIY variant 238 
during viral reactivation. Interestingly, these observations were also evident in other HLA-239 
B44-positive HSCT recipients for both of the HLA-B44 restricted epitopes (Table 3). This was 240 
particularly evident for the EDAIAAYTL variant that could be detected in 6 of 7 HLA B44-241 
positive HSCT recipients but failed to induce a significant T cell response in any recipient. It 242 
is important to mention that we initially aimed to perform longitudinal analysis throughout 243 
the course of viral reactivation in all patients; however in the majority of CMV reactivation 244 
patients tested we were unable to see CMV-specific immune reconstitution until 245 
convalescence. The peak CD8+ T cell response of each patient to each epitope tested is 246 
presented in Supplementary Table 1.  247 
 248 
To further assess the recognition of epitope variants in our recipient cohort, cultured 249 
T cells from all HSCT recipients were stimulated with serial dilutions of both the cognate and 250 
variant peptide and assessed for the production of IFN-γ. The effective concentration (EC) 251 
50 was then calculated based upon the concentration of peptide required to induce 50% of 252 
maximal IFN-γ production. Representative analysis following recall of a YILEETSVML-253 
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stimulated T cell culture with 10-fold serial dilutions of the VLEETSVML and YILEETSVML 254 
epitope variants is shown in Fig 4A.  While T cells specific for HLA-A2 restricted epitopes 255 
(VLEETSVML and YILEETSVML) consistently recognised both variants with similar efficiency 256 
(Fig 3B&C), cross-reactivity towards the HLA-B8 epitopes, ELRRKMMYM and ELKRKMIYM, 257 
was patient-dependent, characterised by preference for a single variant in some individuals 258 
(recipient 17) and cross-reactive in others (recipients 34 and 37) (Fig 4D&E). We saw no 259 
evidence of cross-reactivity in T cells specific for the two B44 restricted epitopes, 260 
DELRRKMMY and EEAIVAYTL which displayed preferential bias for a single variant, 261 
irrespective of evidence for exposure to multiple variants (Fig 4F&G). These observations 262 
further demonstrate that exposure to multiple viral variants does not automatically lead to 263 
the efficient induction of cross-reactive T cell immunity and repertoire "holes" may exist 264 
across genetically unrelated individuals. 265 
 266 
The impact of exposure to multiple viral variants on viral control   267 
We next sought to determine if the reconstitution of the CMV-specific T cell 268 
response directed towards both variant IE-1 and/or conserved epitopes was associated with 269 
viral reactivation. We compared the frequency of CD8+ T cells specific for both IE-1 variant 270 
epitopes and conserved epitopes early (90-106 days) and late (>180 days) post-transplant in 271 
HSCT recipients with and without evidence of reactivation. Pairwise analysis of the 272 
frequency of all detectable CMV-specific T cell responses early and late post-transplant 273 
demonstrated that HSCT recipients with evidence of viral reactivation (Fig 5A) showed less 274 
stability in their T cell responses compared to HSCT recipients without reactivation (Fig 5B). 275 
To contrast the response in R+/D- and R+/D+ patients we assessed the fold change in the 276 
responses early and late post-transplant in these two cohorts. Whilst R+D- recipients with 277 
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reactivation showed significantly greater fold differences in the frequency of CMV-specific T 278 
cells between early and late responses compared to R+D- recipients with no reactivation, we 279 
did not see significant differences in the R+/D+ patients. (Fig 5C). To further assess the 280 
impact of reactivation with multiple viral variants on viral control we compared: (i) the 281 
number of viral reactivations; (ii) the peak viral load and (iii) duration of the first viral 282 
reactivations in HSCT R+/D- and R+/D+ recipients with evidence of single or multiple variants 283 
in their peripheral blood. These analyses revealed no significant differences in the number 284 
of viral reactivations (Fig 5D), in the peak viral load (Fig 5E) or in the duration of reactivation 285 
(Fig 5F) from patients with and without evidence of multiple viral variants. These 286 
observations suggest that whilst the induction of variant specific immunity may play a role 287 
in the control of viral reactivation following reactivation with multiple variants of CMV, the 288 
capacity to induce stable CMV-specific immune reconstitution to either conserved epitopes 289 
or via cross-reactive responses was more relevant for the efficient control of CMV 290 
reactivation following HSCT. 291 
 292 
Discussion 293 
 Observations over the last two decades, particularly with Human Immunodeficiency 294 
Virus (HIV) and other retroviruses, have demonstrated that genetic variation in viral 295 
sequences can have a significant impact upon long-term viral control  (22-24). Unlike these 296 
rapidly mutating retroviruses, T cell immunity to CMV and other human herpes viruses has 297 
typically been shown to be stable with little change in the T cell repertoire (25-27).  298 
However, there is emerging evidence that multiple CMV variants can be found in a single 299 
individual that encode a significant amount of genetic diversity (28, 29). In this study we 300 
sought to assess the impact of genetic diversity and exposure to multiple CMV variants on 301 
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immune mediated control of CMV in HSCT recipients. These analyses revealed that while a 302 
large proportion of HSCT recipients undergoing viral reactivation carry multiple viral 303 
variants, the long-term control of CMV infection is primarily mediated through the efficient 304 
induction of stable reconstitution of T cell immunity irrespective of the nature of the 305 
antigenic target. However, these observations also indicate that the impact of CMV genetic 306 
variation on immunity is complex and larger sample sizes with greater sequencing depth will 307 
likely be require to thoroughly delineate the impact genetic variation has upon the 308 
immunological control of CMV. 309 
  310 
As a major viral complication that has arisen since the advent of HSCT, CMV can lead 311 
to significant morbidity and mortality in immunocompromised patients (7). Complications 312 
associated with CMV infection are most evident in an immunologically naïve setting, 313 
however observations have shown that exposure to CMV can still cause disease irrespective 314 
of prior immunological exposure in immune compromised individuals (3). It has been 315 
suggested that genotypic variation with CMV and exposure to multiple genetic variants may 316 
play a role in clinical outcome. Recent observations have demonstrated that the detection 317 
of multiple CMV genotypes in transplant recipients is common and can be associated with 318 
an increased duration of viral reactivation (12). Although we also detected evidence of 319 
multiple genetic variants of CMV in our cohort of HSCT recipients we did not see any 320 
evidence of an impact on viral reactivation. However, it should be noted that previous 321 
studies were carried out in predominantly SOT recipients using genotypic analysis of surface 322 
glycoproteins, whilst our observations were generated in a cohort of HSCT recipients using 323 
genotypic analysis of IE-1. It could be speculated that differences in these observations 324 
could be attributable to: (i) differences in immunogenicity/protection between 325 
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glycoproteins and IE-1 targets; (ii) the different impact of co-infection in SOT versus HSCT 326 
recipients or (iii) the limited size of our cohort.  327 
 328 
We did observe an association between the stability of CMV-specific T cell immunity 329 
in our R+/D- cohort and viral reactivation. CMV-reactivation patients in this cohort were less 330 
likely to have stable epitope specific T cell responses irrespective of the conserved or variant 331 
nature of the target epitope, compared to patients with no evidence of viral reactivation. 332 
These observations are consistent with previous studies, using different immunological 333 
approaches, demonstrating the association between CMV-reactivation in transplant 334 
patients and poor or unstable CMV-specific T cell immunity. (7, 9, 30, 31). Furthermore, the 335 
stability of this T cell response did not appear to be influenced by the nature of viral 336 
reactivation. CMV reactivation with both multiple or single viral strain was similarly 337 
associated with unstable T cell responses. We were unable to see a similar correlation 338 
between reactivation and T cell immunity in our R+D+ cohort. However this cohort of R+D+ 339 
patients was small, impacting the ability to detect significant differences and the potential 340 
influence of other factors, such as genetic variation between the recipient and donor CMV 341 
isolates. It is also important to appreciate that CMV-specific CD8+ and CD4+ T cell immunity 342 
is directed against a diverse array of antigens and genetic variation within a single CMV gene 343 
may have limited impact on overall immune control. While these observations suggest that 344 
the induction of a robust T cell response is more critical for immune control than the 345 
generation of multi-variant specific immunity, in some individuals we could only detect the 346 
induction of a non-cross-reactive T cell response during viral reactivation, tentatively 347 
suggesting that in some instances an absence of cross-reactivity could be affecting viral 348 
control. 349 
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 350 
 Although we did not see any definitive evidence that the reactivation of multiple 351 
variants impacted upon CMV disease, interestingly, we did observe that some variant 352 
epitopes failed to induce detectable T cell responses which were either cross-reactive or 353 
variant-specific, despite their detection in a large proportion of HSCT recipients (see Table 354 
3). This was particularly evident for the B44-restricted epitope variant EDAIAAYTL for which 355 
we detected no T cells responses, despite the detection of T cells specific for EEAIVAYTL 356 
variants in 50% of HSCT recipients in which the variant sequences were detected. Previous 357 
studies in a number of settings have shown that amino acid sequence changes can restrict 358 
variant peptide recognition, often as a consequence of changes in MHC anchor residues that 359 
result in poor MHC binding or due to restricted T cell repertoire diversity(32-34). Given the 360 
EDAIAAYTL amino acid sequence changes do not occur in MHC anchor residues, our 361 
observations suggest that these variant epitopes may have reduced immunogenicity for 362 
other reasons such as limitations in the T cell repertoire. While the implications for these 363 
observations in the control of viral reactivation are not clear; in settings of adoptive 364 
immunotherapy whereby donor-derived, autologous or third-party T cells are used (35-37), 365 
limited cross-reactivity against variant epitopes could potentially limit the effectiveness of 366 
these T cells for pathogen surveillance.  367 
 368 
In conclusion, the observations in this study provide evidence that exposure to 369 
multiple viral variants in an immune compromised setting is common and does not 370 
necessarily lead to the automatic induction of cross-reactive immunity.  This study also 371 
provides evidence that protection against genetically distinct variants of CMV in infected 372 
individuals is not necessarily dependent upon the induction of cross-reactive T cell 373 
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populations against variant epitopes, but can be efficiently mediated via the recognition of 374 
conserved T cell epitopes. These observations further demonstrate the importance of 375 
robust stable immune reconstitution in the long-term control of CMV following HSCT.  376 
 377 
 378 
 379 
 380 
  381 
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Table 1: Clinical Characteristics of HSCT Recipients included in this study 539 
N.A. Not Applicable 540 
*CMV reactivation defined as CMV DNAemia>600 copies/ml 541 
 542 
 543 
 544 
 545 
Code 
Recipient/ 
Donor 
Serostatus 
HLA Type 
Episodes of 
CMV 
Reactivation 
Maximal 
CMV 
titre 
CMV load >600 
copies/mL 
(days post-
transplant) 
CMV 
Disease 
Patients with CMV reactivation* 
04 R+/D- A2 A29 B44 B51 Cw1 4 10000 60-70; 144-158; 189-195; 363-391 
Yes: CMV 
colitis 
06 R+/D- A23 A26 B39 B51 Cw2 1 900 64-71 No 
13 R+/D- A2 A29 B44 B62 Cw3 Cw16 2 12000 33-67; 77-84 No 
14 R+/D+ A11 A31 B7 B60 6 120000 
46-55; 139-178; 
192-196; 213-
217; 249-269; 
286-314 
Yes; CMV 
enteritis 
16 R+/D- A2 A24 B15 B27 Cw2 Cw3 1 870 69 No 
17 R+/D- A1 A24 B08 B39 Cw7 2 40000 37; 44-68 No 
19 R+/D+ A2 A24 B44 Cw5 3 55000 32-64; 73-80; 88-92 No  
25 R+/D- A2 A3 B35 B62 Cw3 Cw10 2 2400 59; 95-102 No 
26 R+/D- A2 A33 B14 B15 Cw3 Cw8 3 4100 35-60; 81-88; 273-277 No 
28 R+/D- A2 A24 B44 Cw5 Cw6 1 6800 46-67 No 
30 R+/D+ A2 A24 B13 B60 Cw3 Cw4 1 64000 314-332 No 
32 R+/D- A2  B13 B40 Cw3 Cw6 5 22000 39; 49-63; 151-157; 179; 192-237 No 
34 R+/D- A1 A33 B8 B14 Cw7 Cw8 1 2000 57-64 No 
38 R+/D+ A1 A24 B41 B57 Cw6 Cw17 1 1400 75-92 No 
39 R+/D- A2 A29 B44 Cw5 1 6900 45-62 No 
44 R+/D+ A2 A32 B18 B44 Cw5 Cw7 1 1000 43-48 No 
46 R+/D- A2 B27 B44 Cw2 Cw5 2 2800 32-35; 53 No  
Patients without CMV reactivation 
01 R+/D- A1 A3 B27 B60 Cw2 Cw3 N.A N.A N.A No 
07 R-/D+ A1 A2 B08 B15 Cw3 Cw7 N.A N.A N.A No 
15 R+/D- A3 A31 B7 B60 Cw3 Cw7 N.A N.A N.A No
36 R+/D- A1 A2 B35 B62 Cw3 Cw4 N.A N.A N.A No
37 R+/D- A2 A23 B15 B44 Cw4 Cw7 N.A N.A N.A No
42 R+/D+ A2 A23 B15 B44 Cw4 Cw7 N.A N.A N.A No
43 R+/D+ A1 A26 B44 B13 Cw7 N.A N.A N.A No
45 R+/D- A1 A2 B37 B44 Cw5 Cw6 N.A N.A N.A No
47 R+/D+ A2 B7 B44 Cw5 Cw7 N.A N.A N.A No
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Table 2: List of IE-1 Epitope Variants used in this study 546 
Epitope HLA Restriction 
Sequence 
Position 
Major Epitope 
Variant 
Amino Acid 
Variant; 
Position (P) 
Reference 
KARAKKDELR A31 192-201 KARAKKDELK R/K P10 This study
ARAKKDELR B27 193-201 ARAKKDELK R/K P9 This study
DELRRKMMY B18; B44 198-206 DELKRKMIY R/K P4;        M/I P8 (17) 
ELRRKMMYM B8 199-207 ELKRKMIYM R/K P3;        M/I P7 (19) 
RRKMMYMYCR B27 201-210 KRKMIYMYCR R/K P1M/I P5 This study 
AYAQKIFKIL A23 248-257 TYSQKIFKIL A/T P1;        A/S P3 (20, 21) 
VLEETSVML A2 316-324 YILEETSVML V/I P1 or P2; (18) 
EEAIVAYTL B18; B44 381-390 EDAIAAYTL E/D P2;        V/A P5 (17) 
 547 
  548 
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Table 3: Summary of CMV-specific peptide epitope recognition by HSCT recipients 549 
Peptide  
Sequence 
Reactivation
 
No Reactivation 
Number of 
HLA 
Matched 
Recipients  
Number of 
HLA 
Matched 
Recipients 
with 
sequence 
detected
Number of 
Responders#
Number of 
HLA 
Matched 
Recipients
Number of 
Responders# 
VLEETSVML 12 7 3 5 1 
YILEETSVML 12 5 4 5 2 
DELRRKMMY 7 5 2 4 0 
DELKRKMIY 7 3 1 4 0 
EEAIAVAYL 7 4 2 4 0 
EDAIAAYTL 7 6 0 4 0 
ELRRKMMYM 2 2 1 2 2 
ELKRKMIYM 2 1 2 2 2 
AYAQKIFKIL 1 0 1 1 0 
TYSQKIFKIL 1 1 1 1 1 
KARAKKDELR 1 1 0 1 0 
KARAKKDELK 1 0 0 1 0 
ARAKKDELK  1 1 1 1 0 
ARAKKDELR 1 1 1 1 0 
KRKMIYMCYR 1 0 0 1 1 
RRKMMYMCYR 1 1 1 1 1 
FMDILTTCV 12 N.D. 5 5 0 
NLVPMVATV 12 N.D. 8 5 3 
RPHERNGFTVL 1 N.D. 1 1 1 
TPRVTGGGAM 1 N.D. 1 1 1 
VTEHDTLLY 3 N.D. 3 4 3 
QIKVRVDMV 2 N.D. 1 1 1 
YSEHPTFTSQY 0 N.D. 0 2 2 
N.D. Not Done 550 
# Patients with >5% of CD8+ T cells producing IFN-γ following recall after  two weeks of 551 
culture were considered Responders 552 
  553 
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Figure 1: Pyrosequencing analysis of the IE-1 sequence variants in HSCT recipients. DNA 554 
was extracted from plasma samples of 17 HSCT recipients during CMV reactivation. 555 
Following DNA PCR amplification, pyrosequencing analysis of the panel of SNPs was 556 
performed as outlined in the Materials and Methods. The nucleotide data was extrapolated 557 
to determine the proportion of each amino acid residue for the 8 positions tested. (A) Data 558 
represents the proportion of R+/D- recipient samples encoding either a dominant single 559 
amino acid residue at each position or both amino acid residues at each position. (B) Data 560 
represents the proportion of R+/D+ recipient samples encoding either a dominant single 561 
amino acid residue at each position or both amino acid residues at each position.  562 
 563 
Figure 2: Longitudinal pyrosequencing analysis in HSCT recipients. Longitudinal 564 
pyrosequencing analysis was performed in HSCT patients from whom more than a single 565 
timepoint of viral reaction was available. Each data line represents individual SNPs over time 566 
following a single or multiple rounds of viral reactivation.  567 
 568 
Figure 3: The kinetics of variant-specific T cell activation following viral reactivation in 569 
HSCT transplant recipients. Longitudinal PBMC from HSCT recipients during and after CMV 570 
reactivation were stimulated with HLA-matched IE-1 encoded variant peptide epitopes and 571 
control non-variant peptides, then cultured in vitro for two weeks in the presence of IL-2. 572 
Two weeks later T cell cultures were recalled with cognate peptide and assessed for the 573 
intracellular expression of IFN-γ. Representative data from three HSCT recipients overlaid 574 
with the kinetics of viral reactivation are shown. (A) PBMC from recipient 14 were assessed 575 
for T cell responses on days 40, 47, 54, 68, 82 and 96 post-transplant. (B) PBMC from 576 
recipient 28 were assessed for T cell responses on days 41, 60, 67, 97 and 370 post-577 
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transplant. (C) PBMC from recipient 44 were assessed for T cell responses on days 48, 68 578 
and 364 post-transplant. Representative data of the frequency of each variant amino acid 579 
residue relevant to the T cell responses shown in panels A-C at the peak of viral reactivation 580 
is shown for recipient 17 (D), recipient 28 (E) and recipient 44 (F). 581 
* No response detected. 582 
 583 
Figure 4: Functional avidity analysis of IE-1 variant specific T cell populations.  Following in 584 
vitro expansion for two weeks in the presence of cognate peptide and IL-2, IE-1 epitope 585 
specific T cells were incubated for four hours with ten-fold serial dilutions of both the 586 
cognate peptide and the epitope variant. IFN-γ expression was then assessed using an 587 
intracellular cytokine assay. The EC50 was calculated based upon the peptide concentration 588 
required to induce activation in 50% of the maximal number of IFN-γ producing cells. (A) 589 
Representative peptide titration from YILEETSVML-stimulated T cell cultures from patient 47 590 
recalled with VLEETSVML and YILEETSVML is shown. Data in bottom rows correspond to T 591 
cell stimulated ex vivo with VLEETSVML (B), YILEETSVML (C), ELRRKMMYM (D), ELKRKMIYM 592 
(E), DELRRKMMY (F) and EEAIVAYTL (G). Legends at the bottom of each row correspond to 593 
the cognate and variant peptides used to recall the T cells response after two weeks in 594 
culture.  595 
 596 
Figure 5: Effect of co-infection on viral reactivations and the association of viral 597 
reactivation with overall T cell immunity. (A-C) Pairwise analysis of the frequency of IFN-γ 598 
producing T cells generated against individual epitopes from HSCT recipients showing 599 
evidence of reactivation (A) or with no evidence of reactivation (B) are shown. Responses 600 
are only shown when epitope-specific T cells were detected in at least one time point.  Data 601 
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in red represents R+/D+ patients, data in black represents R+/D- patients. Fold difference (C) 602 
was calculated by dividing the higher frequency of IFN-γ T cells, at either timepoint, by the 603 
lower frequency detected at either time point. (D-F) HSCT recipients were grouped based 604 
upon whether they showed evidence for exposure to multiple variants. (D) Data represents 605 
the number of reactivations in HSCT recipients with and without evidence of co-infection. 606 
(E) Data represents the viral load during primary reactivation. (F) Data represents the 607 
duration in days of the primary reactivation. 608 
 o
n
 July 17, 2017 by CARDIFF UNIVERSITY
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 July 17, 2017 by CARDIFF UNIVERSITY
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 July 17, 2017 by CARDIFF UNIVERSITY
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 July 17, 2017 by CARDIFF UNIVERSITY
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 July 17, 2017 by CARDIFF UNIVERSITY
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 July 17, 2017 by CARDIFF UNIVERSITY
http://jvi.asm.org/
D
ow
nloaded from
 
